Bliss GVS Pharma Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹90.6
- Today's High:
- ₹96.6
- Open Price:
- ₹95.95
- 52W Low:
- ₹68.1609
- 52W High:
- ₹103.9
- Prev. Close:
- ₹95.4
- Volume:
- 341511
Company Statistics
- Market Cap.:
- ₹10.24 billion
- Book Value:
- 84.866
- Revenue TTM:
- ₹7.22 billion
- Operating Margin TTM:
- 11.4%
- Gross Profit TTM:
- ₹3.38 billion
- Profit Margin:
- 8.28%
- Return on Assets TTM:
- 5.44%
- Return on Equity TTM:
- 8.7%
Company Profile
Bliss GVS Pharma Limited had its IPO on under the ticker symbol BLISSGVS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Bliss GVS Pharma Limited has a staff strength of 763 employees.
Stock update
Shares of Bliss GVS Pharma Limited opened at ₹95.95 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹90.6 - ₹96.6, and closed at ₹91.2.
This is a -4.4% slip from the previous day's closing price.
A total volume of 341,511 shares were traded at the close of the day’s session.
In the last one week, shares of Bliss GVS Pharma Limited have slipped by -5.79%.
Bliss GVS Pharma Limited's Key Ratios
Bliss GVS Pharma Limited has a market cap of ₹10.24 billion, indicating a price to book ratio of 0.8914 and a price to sales ratio of 1.3416.
In the last 12-months Bliss GVS Pharma Limited’s revenue was ₹7.22 billion with a gross profit of ₹3.38 billion and an EBITDA of ₹1.00 billion. The EBITDA ratio measures Bliss GVS Pharma Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bliss GVS Pharma Limited’s operating margin was 11.4% while its return on assets stood at 5.44% with a return of equity of 8.7%.
In Q2, Bliss GVS Pharma Limited’s quarterly earnings growth was a negative -43.4% while revenue growth was a negative 15.4%.
Bliss GVS Pharma Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 17.3286
- PEG
Its diluted EPS in the last 12-months stands at ₹5.66 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bliss GVS Pharma Limited’s profitability.
Bliss GVS Pharma Limited stock is trading at a EV to sales ratio of 1.2597 and a EV to EBITDA ratio of 5.8917. Its price to sales ratio in the trailing 12-months stood at 1.3416.
Bliss GVS Pharma Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 8.81%.
Balance sheet and cash flow metrics
- Total Assets
- ₹11.57 billion
- Total Liabilities
- ₹1.93 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 8.81%
Bliss GVS Pharma Limited ended 2024 with ₹11.57 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹11.57 billion while shareholder equity stood at ₹8.84 billion.
Bliss GVS Pharma Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹1.93 billion in other current liabilities, in common stock, ₹8.15 billion in retained earnings and ₹77.11 million in goodwill. Its cash balance stood at ₹249.55 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹406.90 million.
Bliss GVS Pharma Limited’s total current assets stands at ₹6.97 billion while long-term investments were ₹0 and short-term investments were ₹872.00 million. Its net receivables were ₹3.85 billion compared to accounts payable of ₹863.90 million and inventory worth ₹1.03 billion.
In 2024, Bliss GVS Pharma Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Bliss GVS Pharma Limited paid ₹0.09 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹91.2
- 52-Week High
- ₹103.9
- 52-Week Low
- ₹68.1609
- Analyst Target Price
- ₹
Bliss GVS Pharma Limited stock is currently trading at ₹91.2 per share. It touched a 52-week high of ₹103.9 and a 52-week low of ₹103.9. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹93.01 and 200-day moving average was ₹79.24 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6548.2% of the company’s stock are held by insiders while 899.4% are held by institutions.
Frequently Asked Questions About Bliss GVS Pharma Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as soaps. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.